Last update Oct. 20, 2023

Dihydroergocryptyne Mesilate

Incompatible

Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Commentary.

Dihydroergocryptine mesylate is a derivative of ergot, a component of codergocrine mesylate, and has similar actions. It has been used in the treatment of migraine, parkinsonism, senile dementia, cerebrovascular and peripheral vascular disorders, prolactinomas and to inhibit lactation. Oral administration.

At the time of the last update, we found no published data on its excretion in breast milk.

Like all ergot derivatives, it is a dopaminergic agonist and therefore reduces prolactin secretion and may suppress lactation. (Mirkou 2012, Nappi 1993)


See below the information of these related products:

  • Co-dergocrine Mesilate, codergocrine (Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Commentary.)
  • Ergot Fungus (Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Commentary.)

Alternatives

We do not have alternatives for Dihydroergocryptyne Mesilate.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Dihydroergocryptyne Mesilate in other languages or writings:

Group

Dihydroergocryptyne Mesilate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Dihydroergocryptyne Mesilate in its composition:

List of 6 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. baja-los %
Molecular weight 674 daltons
Tmax 3 hours
T½ 25 hours

References

  1. [No authors listed] Do not use drugs to prevent onset of lactation. Relieve the discomfort and wait. Prescrire Int. 2013 Abstract
  2. Mirkou A, Suchovsky D, Gouraud A, Gillet A, Bernard N, Descotes J, Vial T. [Prescription of ergot derivatives for lactation inhibition in France: Current practices]. J Gynecol Obstet Biol Reprod (Paris). 2012 Apr;41(2):167-73. Abstract Full text (link to original source)
  3. Ronca F, Guazzelli M, Salvadori P, Palumbo R, Neuteboom B, Ambrosoli L, Poli A, Girardello R, Lowenthal DT. Pharmacokinetic and Metabolism Study in Healthy Volunteers After Administration of Single Oral Dose of (3)H-alpha-Dihydroergocryptine Mesylate. Am J Ther. 1996 Aug;3(8):553-562. Abstract
  4. Nappi C, Colace G, Di Carlo C, Affinito P, Ruotolo C, Montemagno R, Farace MJ, Mailland F, Di Renzo GF. Effect of dihydroergocryptine on serum prolactin levels and milk secretion in puerperal women. Gynecol Endocrinol. 1993 Jun;7(2):129-33. Abstract

Total visits

5,813

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM